Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Schizophrenia is associated with a broad range of neurodevelopmental, structural and behavioral abnormalities that often progress with or without treatment. Evidence indicates that such neurodevelopmental abnormalities may result from defective genes and/or non-genetic factors such as pre-natal and neonatal infections, birth complications, famines, maternal malnutrition, drug and alcohol abuse, season of birth, sex, birth order and life style. Experimentally, these factors have been found to cause the cellular metabolic stress that often results in oxidative stress, such as increased cellular levels of reactive oxygen species (ROS) over the antioxidant capacity. This can trigger the oxidative cell damage (i.e., DNA breaks, protein inactivation, altered gene expression, loss of membrane lipid-bound essential polyunsaturated fatty acids [EPUFAs] and often apoptosis) contributing to abnormal neural growth and differentiation. The brain is preferentially susceptible to oxidative damage since it is under very high oxygen tension and highly enriched in ROS susceptible proteins, lipids and poor DNA repair. Evidence is increasing for increased oxidative stress and cell damage in schizophrenia. Furthermore, treatments with some anti-psychotics together with the lifestyle and dietary patterns, that are pro-oxidant, can exacerbate the oxidative cell damage and trigger progression of neuropathology. Therefore, adjunctive use of dietary antioxidants and EPUFAs, which are known to regulate the growth factors and neuroplasticity, can effectively improve the clinical outcome. The dietary supplementation of either antioxidants or EPUFAs, particularly omega-3 has already been found to improve some psychopathologies. However, a combination of antioxidants and omega-3 EPUFAs, particularly in the early stages of illness, when brain has high degree of neuroplasticity, potentially may be even more effective for long-term improved clinical outcome of schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Omega-3 fatty acids in health and disease and in growth and development.
Simopoulos, A. (1991) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/54.3.438 · Cited by 2,162 · cited 1×
“The role of omega-3 fatty acids in preservation and performance of brain and body has been well documented (Simopoulos, 1991).”
BackgroundSchizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
Ascorbate is an outstanding antioxidant in human blood plasma
Frei, B., England, L., & Ames, B. N. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.16.6377 · Cited by 1,870
Jablensky, A., Sartorius, N., Ernberg, G., Anker, M., Korten, A., Cooper, J. E., Day, R., & Bertelsen, A. (1992) · Psychological Medicine. Monograph Supplement · doi:10.1017/s0264180100000904 · Cited by 1,769
Halliwell, B. (2001) · Drugs & Aging · doi:10.2165/00002512-200118090-00004 · Cited by 1,502
Sohal, R. S., Ku, H.-H., Agarwal, S., Forster, M. J., & Lal, H. (1994) · Mechanisms of Ageing and Development · doi:10.1016/0047-6374(94)90104-x · Cited by 788
Gur, R. E., Cowell, P., Turetsky, B. I., Gallacher, F., Cannon, T., Bilker, W., & Gur, R. C. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.2.145 · Cited by 540
Wu, A., Ying, Z., & Gomez-Pinilla, F. (2004) · Journal of Neurotrauma · doi:10.1089/neu.2004.21.1457 · Cited by 518
Urakubo, A., Jarskog, L. F., Lieberman, J. A., & Gilmore, J. H. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00032-3 · Cited by 405
Horrocks, L. A., & Farooqui, A. A. (2004) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2003.12.011 · Cited by 356 · cited 1×
“Recently, several extensive reviews and chapters have been published on this topic (Das, 2004; Horrocks & Farooqui, 2004; Mahadik & Evans, 1997; Mahadik, Evans, & Lal, 2001; Peet, Laugharne, Mellor, & Ramchand, 1996; Peet & Stokes, 2005).”
Cited by
Mitochondrial electron transport chain, ROS generation and uncoupling (Review)
Zhao, R., Jiang, S., Zhang, L., & Yu, Z. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4188 · Cited by 1,386
Oxidative stress and human diseases: Origin, link, measurement, mechanisms, and biomarkers
Giustarini, D., Dalle-Donne, I., Tsikas, D., & Rossi, R. (2009) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408360903142326 · Cited by 440
Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: An overview
Mazza, M., Pomponi, M., Janiri, L., Bria, P., & Mazza, S. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.07.010 · Cited by 306
Antioxidants, Redox Signaling, and Pathophysiology in Schizophrenia: An Integrative View
Yao, J. K., & Keshavan, M. S. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3603 · Cited by 285
“Examples of such interventions include dietary supplementation with a combination of n-3 PUFAs and antioxidants for treatment of SZ patients, particularly in the early stages of illness (59, 155), and in reducing the risk of progression to psychotic disorder in patients with prodromal symptoms (4), and the use of Nace…”
Sivrioglu, E. Y., Kirli, S., Sipahioglu, D., Gursoy, B., & Sarandöl, E. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.07.004 · Cited by 102
Metadata
- Authors
- Mahadik, S. P., Pillai, A., Joshi, S., & Foster, A.
- Venue
- International Review of Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2006-01
- Volume
- 18
- Issue
- 2
- Pages
- 119-131
- ISSN
- 0954-0261 (ISSN-L)
- 1369-1627
- OpenAlex
- W2098248193
- Cited by
- 98
- References
- 12
- FWCI
- 5.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. https://app.cochat.ai/papers/10.1080/09540260600581993
- The paper
- Mahadik, S. P., Pillai, A., Joshi, S., & Foster, A. (2006). Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. International Review of Psychiatry. https://doi.org/10.1080/09540260600581993
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.